Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Neos Therapeutics, Inc. (NASDAQ: NEOS).

Full DD Report for NEOS

You must become a subscriber to view this report.


Recent News from (NASDAQ: NEOS)

Neos Therapeutics to Present at the UBS Global Healthcare Conference
DALLAS and FORT WORTH, Texas, May 15, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery technologies...
Source: GlobeNewswire
Date: May, 15 2018 08:00
Neos Therapeutics' (NEOS) CEO Vipin Garg on Q1 2018 Results - Earnings Call Transcript
Neos Therapeutics (NEOS) Q1 2018 Results Earnings Conference Call May 9, 2018, 08:30 AM ET Executives Vipin Garg - President and CEO Richard Eisenstadt - CFO Thomas McDonnell - Chief Commercial Officer Analysts Katie Kerfoot - Wells Fargo Roy Buchanan - JMP Securities J...
Source: SeekingAlpha
Date: May, 09 2018 12:40
Neos Therapeutics misses by $0.03, beats on revenue
Neos Therapeutics (NASDAQ: NEOS ): Q1 EPS of -$0.50 misses by $0.03 . More news on: Neos Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 09 2018 07:01
Neos Therapeutics Reports First Quarter 2018 Financial Results
DALLAS and FORT WORTH, Texas, May 09, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc.   (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery techn...
Source: GlobeNewswire
Date: May, 09 2018 07:00
How To Play 'Am I Diversified?' In The Pharma/Biotech Space
Background Many investors (including myself) regularly watch or listen to the show "Mad Money" by Jim Cramer on CNBC. As with any celebrity, Mr. Cramer tends to be polarizing, with some loving him and some reveling in pointing out when he is wrong. Rather than focusing on his individual stoc...
Source: SeekingAlpha
Date: May, 03 2018 00:54
Neos Therapeutics to Host First Quarter 2018 Financial Results Conference Call on May 9, 2018
DALLAS and FORT WORTH, Texas, May 02, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery technologies...
Source: GlobeNewswire
Date: May, 02 2018 07:30
Research Report Identifies Flexsteel Industries, Second Sight Medical Products, XG Technology, CRA International, Inc, Neos Therapeutics, and Tech Data with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Flexsteel Industries, Inc. (NASDAQ:FLXS), Second Sight Medical Products, I...
Source: GlobeNewswire
Date: May, 01 2018 08:10
Factors of Influence in 2018, Key Indicators and Opportunity within REX American Resources, CRA International, City Holding, Safety Insurance Group, Neos Therapeutics, and City Office REIT - New Research Emphasizes Economic Growth
NEW YORK, March 22, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of REX American Resources Corporation (NYSE:REX), CRA International, Inc. (...
Source: GlobeNewswire
Date: March, 22 2018 08:30
Biotech Forum Daily Digest For March 19th
"There are two ways to be fooled. One is to believe what isn't true; the other is to refuse to believe what is true." - Søren Kierkegaard After a big surge last week, the markets largely spent this week drifting down and giving back a portion of the previous week's rally. For the week...
Source: SeekingAlpha
Date: March, 19 2018 11:42
Neos Therapeutics' (NEOS) CEO Vipin Garg on Q4 2017 Results - Earnings Call Transcript
Start Time: 08:30 End Time: 09:03 Neos Therapeutics, Inc. (NEOS) Q4 2017 Earnings Conference Call March 15, 2018, 08:30 AM ET Executives Vipin Garg - President and CEO Richard Eisenstadt - CFO Thomas McDonnell - Chief Commercial Officer Analysts David Maris - Wells Farg...
Source: SeekingAlpha
Date: March, 15 2018 12:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-06-206.456.606.656.40120,841
2018-06-196.656.456.806.40237,890
2018-06-186.706.656.756.6099,604
2018-06-156.856.706.8756.65252,912
2018-06-146.806.806.906.50608,480

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-06-2117,82054,45232.7261Cover
2018-06-2023,25936,34363.9986Short
2018-06-1928,64958,45349.0120Short
2018-06-183,79921,71717.4932Cover
2018-06-1513,96443,40432.1722Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NEOS.


About Neos Therapeutics, Inc. (NASDAQ: NEOS)

Logo for Neos Therapeutics, Inc. (NASDAQ: NEOS)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $213,127,627 - 05/11/2018
  • Issue and Outstanding: 28,996,956 - 11/03/2017

 


Recent Filings from (NASDAQ: NEOS)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: May, 02 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 27 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 16 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 15 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: NEOS)

Daily Technical Chart for (NASDAQ: NEOS)


Stay tuned for daily updates and more on (NASDAQ: NEOS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: NEOS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NEOS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of NEOS and does not buy, sell, or trade any shares of NEOS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/